Pfizer Experiences Slight Decline in Trading

1 min read | September 26, 2024 01:31 PM PDT | By Team Kalkine Media

Google News:

Pfizer Experiences Slight Decline in Trading — Image source: Shutterstock

Recent News

Why is Marathon Petroleum (NYSE:MPC) moving with S&P 500 Energy?

Why AbbVie (NYSE:ABBV) Gains in S&P 500 Index Biopharma Push?

Why FactSet Research Systems Anchors Index Stability Gains Now?

Why Is M&T Bank Driving S&P 500 Index Regional Banking Strength?

Make Kalkine Media
My Trusted Source

Headlines

Pfizer Inc. experienced a modest decline in stock price, trading at approximately $28.76.

Several brokerages have adjusted their target prices, with a mix of ratings reflecting varied perspectives on the stock’s performance.

Analyst opinions indicate a generally favorable outlook, with most ratings leaning towards positive assessments.

Pfizer Inc. (NYSE:PFE) faced a slight decrease in its stock price, trading at around $28.76 during midday on Thursday. The stock saw fluctuations, trading as low as $28.31. Trading volume reflected notable activity, although it was significantly lower than the average session volume. Various brokerages have recently provided insights into Pfizer’s market position. Barclays adjusted its target price upwards and rated the stock as equal weight. UBS Group also raised its target price, reflecting a neutral stance on the stock. Daiwa Capital Markets upgraded Pfizer from neutral to outperform, indicating a more optimistic outlook, while Cantor Fitzgerald reaffirmed a positive rating with a higher price target. Overall, the assessments from multiple analysts suggest a generally favorable view of Pfizer’s prospects, despite the recent price movement.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.